The approach of pairing an ecological framework with AI methods offers a new way to identify where diabetes risk concentrates.

Built from the experiences of patients, advocates and clinicians, a new MASH patient journey map offers a roadmap for navigating diagnosis and highlights the need for greater public understanding of the disease.

Financial sustainability and innovation are interdependent, as clinician-led contracting strategies that improve outcomes generate savings that fund further innovation.

A new meta-analysis suggests that combining immunotherapy and chemotherapy might be the best choice for treating advanced non-small cell lung cancer.

Addressing social determinants of health is now a strategic pillar of organizational planning, compliance, and long-term sustainability.

Results from the DAPHNe trial point to ctDNA as having a role in guiding treatment, but the researchers and a commentator say more research needs to be done before determining exactly what it is.

Age, skin phototype, and personal history of skin cancer are easily captured data elements that could form the basis of a practical, risk-stratified approach to surveillance.

The two conditions can have similar manifestations but differ in prognosis and treatment, which makes an accurate, early diagnosis important.

Survodutide is a dual GLP-1/glucagon receptor agonist that was also able to normalize liver fat in 61% of patients with metabolic dysfunction-associated steatotic liver disease.